Skip to main content
Erschienen in: Cellular Oncology 2/2017

30.12.2016 | Original Paper

HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation

verfasst von: Suresh Bugide, Vijay Kumar Gonugunta, Vasudevarao Penugurti, Vijaya Lakshmi Malisetty, Ratna K. Vadlamudi, Bramanandam Manavathi

Erschienen in: Cellular Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hematopoietic PBX interacting protein (HPIP), a scaffold protein, is known to regulate the proliferation, migration and invasion in different cancer cell types. The aim of this study was to assess the role of HPIP in ovarian cancer cell migration, invasion and epithelial-mesenchymal transition (EMT), and to unravel the mechanism by which it regulates these processes.

Methods

HPIP expression was assessed by immunohistochemistry of tissue microarrays containing primary ovarian tumor samples of different grades. OAW42, an ovarian carcinoma-derived cell line exhibiting a high HPIP expression, was used to study the role of HPIP in cell migration, invasion and EMT. HPIP knockdown in these cells was achieved using a small hairpin RNA (shRNA) approach. Cell migration and invasion were assessed using scratch wound and transwell invasion assays, respectively. The extent of EMT was assessed by determining the expression levels of Snail, Vimentin and E-cadherin using Western blotting. The effect of HPIP expression on AKT and MAPK activation was also investigated by Western blotting. Cell viabilities in response to cisplatin treatment were assessed using a MTT assay, whereas apoptosis was assessed by determining caspase-3 and PARP cleavage in ovarian carcinoma-derived SKOV3 cells.

Results

We found that HPIP is highly expressed in high-grade primary ovarian tumors. In addition, we found that HPIP promotes the migration, invasion and EMT in OAW42 cells and induces EMT in these cells via activation of the PI3K/AKT pathway. The latter was found to lead to stabilization of the Snail protein and to repression of E-cadherin expression through inactivation of GSK-3β. We also found that HPIP expression confers cisplatin resistance to SKOV3 cells after prolonged exposure and that its subsequent knockdown decreases the viability of these cells and increases caspase-3 activation and PARP proteolysis in these cells following cisplatin treatment.

Conclusions

From these results we conclude that HPIP expression is associated with high-grade ovarian tumors and may promote their migration, invasion and EMT, a process that is associated with metastasis. In addition, we conclude that HPIP may serve as a potential therapeutic target for cisplatin resistant ovarian tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat R.P. Perez, A.K. Godwin, T.C. Hamilton, R.F. Ozols, Ovarian cancer biology. Semin Oncol 18, 186–204 (1991)PubMed R.P. Perez, A.K. Godwin, T.C. Hamilton, R.F. Ozols, Ovarian cancer biology. Semin Oncol 18, 186–204 (1991)PubMed
6.
Zurück zum Zitat M. Zou, X. Zhang, C. Xu, IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells. Cell Oncol 39, 47–57 (2016). doi:10.1007/s13402-015-0251-7 CrossRef M. Zou, X. Zhang, C. Xu, IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells. Cell Oncol 39, 47–57 (2016). doi:10.​1007/​s13402-015-0251-7 CrossRef
9.
Zurück zum Zitat J. Mikula-Pietrasik, P. Uruski, K. Matuszkiewicz, S. Szubert, R. Moszynski, D. Szpurek, S. Sajdak, A. Tykarski, K. Ksiazek, Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol 39, 473–481 (2016). doi:10.1007/s13402-016-0289-1 CrossRef J. Mikula-Pietrasik, P. Uruski, K. Matuszkiewicz, S. Szubert, R. Moszynski, D. Szpurek, S. Sajdak, A. Tykarski, K. Ksiazek, Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol 39, 473–481 (2016). doi:10.​1007/​s13402-016-0289-1 CrossRef
10.
Zurück zum Zitat Y. Kuwabara, T. Yamada, K. Yamazaki, W.L. Du, K. Banno, D. Aoki, M. Sakamoto, Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci 99, 1933–1939 (2008). doi:10.1111/j.1349-7006.2008.00946.x PubMed Y. Kuwabara, T. Yamada, K. Yamazaki, W.L. Du, K. Banno, D. Aoki, M. Sakamoto, Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci 99, 1933–1939 (2008). doi:10.​1111/​j.​1349-7006.​2008.​00946.​x PubMed
12.
15.
Zurück zum Zitat X. Xu, Z. Fan, L. Kang, J. Han, C. Jiang, X. Zheng, Z. Zhu, H. Jiao, J. Lin, K. Jiang, L. Ding, H. Zhang, L. Cheng, H. Fu, Y. Song, Y. Jiang, J. Liu, R. Wang, N. Du, Q. Ye, Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123, 630–645 (2013). doi:10.1172/JCI64265 PubMedPubMedCentral X. Xu, Z. Fan, L. Kang, J. Han, C. Jiang, X. Zheng, Z. Zhu, H. Jiao, J. Lin, K. Jiang, L. Ding, H. Zhang, L. Cheng, H. Fu, Y. Song, Y. Jiang, J. Liu, R. Wang, N. Du, Q. Ye, Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123, 630–645 (2013). doi:10.​1172/​JCI64265 PubMedPubMedCentral
16.
Zurück zum Zitat S. Bugide, D. David, A. Nair, N. Kannan, V.S. Samanthapudi, J. Prabhakar, B. Manavathi, Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics. Oncogene 34, 4601–4612 (2015). doi:10.1038/onc.2014.389 CrossRefPubMed S. Bugide, D. David, A. Nair, N. Kannan, V.S. Samanthapudi, J. Prabhakar, B. Manavathi, Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics. Oncogene 34, 4601–4612 (2015). doi:10.​1038/​onc.​2014.​389 CrossRefPubMed
17.
Zurück zum Zitat Y. Feng, X. Xu, Y. Zhang, J. Ding, Y. Wang, X. Zhang, Z. Wu, L. Kang, Y. Liang, L. Zhou, S. Song, K. Zhao, Q. Ye, HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci Rep 5, 9429 (2015). doi:10.1038/srep09429 CrossRefPubMedPubMedCentral Y. Feng, X. Xu, Y. Zhang, J. Ding, Y. Wang, X. Zhang, Z. Wu, L. Kang, Y. Liang, L. Zhou, S. Song, K. Zhao, Q. Ye, HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci Rep 5, 9429 (2015). doi:10.​1038/​srep09429 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Y. Feng, L. Li, X. Zhang, Y. Zhang, Y. Liang, J. Lv, Z. Fan, J. Guo, T. Hong, B. Ji, Q. Ji, G. Mei, L. Ding, S. Zhang, X. Xu, Q. Ye, HPIP is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration and invasion. Cancer Sci 106, 1313–1322 (2015). doi:10.1111/cas.12754 CrossRefPubMedPubMedCentral Y. Feng, L. Li, X. Zhang, Y. Zhang, Y. Liang, J. Lv, Z. Fan, J. Guo, T. Hong, B. Ji, Q. Ji, G. Mei, L. Ding, S. Zhang, X. Xu, Q. Ye, HPIP is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration and invasion. Cancer Sci 106, 1313–1322 (2015). doi:10.​1111/​cas.​12754 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat S. Okada, T. Irie, J. Tanaka, R. Yasuhara, G. Yamamoto, T. Isobe, C. Hokazono, T. Tachikawa, Y. Kohno, K. Mishima, Potential role of hematopoietic pre-B-cell leukemia transcription factor-interacting protein in oral carcinogenesis. J Oral Pathol Med 44, 115–125 (2015). doi:10.1111/jop.12210 CrossRefPubMed S. Okada, T. Irie, J. Tanaka, R. Yasuhara, G. Yamamoto, T. Isobe, C. Hokazono, T. Tachikawa, Y. Kohno, K. Mishima, Potential role of hematopoietic pre-B-cell leukemia transcription factor-interacting protein in oral carcinogenesis. J Oral Pathol Med 44, 115–125 (2015). doi:10.​1111/​jop.​12210 CrossRefPubMed
22.
Zurück zum Zitat D.G. van Vuurden, E. Aronica, E. Hulleman, L.E. Wedekind, D. Biesmans, A. Malekzadeh, M. Bugiani, D. Geerts, D.P. Noske, W.P. Vandertop, G.J. Kaspers, J. Cloos, T. Wurdinger, P.P. van der Stoop, Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology 16, 946–959 (2014). doi:10.1093/neuonc/not308 CrossRefPubMedPubMedCentral D.G. van Vuurden, E. Aronica, E. Hulleman, L.E. Wedekind, D. Biesmans, A. Malekzadeh, M. Bugiani, D. Geerts, D.P. Noske, W.P. Vandertop, G.J. Kaspers, J. Cloos, T. Wurdinger, P.P. van der Stoop, Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology 16, 946–959 (2014). doi:10.​1093/​neuonc/​not308 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat K. Shostak, F. Patrascu, S.I. Goktuna, P. Close, L. Borgs, L. Nguyen, F. Olivier, A. Rammal, H. Brinkhaus, M. Bentires-Alj, J.C. Marine, A. Chariot, MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation. Cell Death Differ 21, 811–824 (2014). doi:10.1038/cdd.2014.2 CrossRefPubMedPubMedCentral K. Shostak, F. Patrascu, S.I. Goktuna, P. Close, L. Borgs, L. Nguyen, F. Olivier, A. Rammal, H. Brinkhaus, M. Bentires-Alj, J.C. Marine, A. Chariot, MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation. Cell Death Differ 21, 811–824 (2014). doi:10.​1038/​cdd.​2014.​2 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat V.N. Gajulapalli, V.S. Samanthapudi, M. Pulaganti, S.S. Khumukcham, V.L. Malisetty, L. Guruprasad, S.K. Chitta, B. Manavathi, A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells. Biochem J 473, 1047–1061 (2016). doi:10.1042/BCJ20160019 CrossRefPubMed V.N. Gajulapalli, V.S. Samanthapudi, M. Pulaganti, S.S. Khumukcham, V.L. Malisetty, L. Guruprasad, S.K. Chitta, B. Manavathi, A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells. Biochem J 473, 1047–1061 (2016). doi:10.​1042/​BCJ20160019 CrossRefPubMed
25.
Zurück zum Zitat G.R. Sareddy, B.C. Nair, S.K. Krishnan, V.K. Gonugunta, Q.G. Zhang, T. Suzuki, N. Miyata, A.J. Brenner, D.W. Brann, R.K. Vadlamudi, KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 4, 18–28 (2013). doi:10.18632/oncotarget.725 PubMed G.R. Sareddy, B.C. Nair, S.K. Krishnan, V.K. Gonugunta, Q.G. Zhang, T. Suzuki, N. Miyata, A.J. Brenner, D.W. Brann, R.K. Vadlamudi, KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 4, 18–28 (2013). doi:10.​18632/​oncotarget.​725 PubMed
26.
Zurück zum Zitat T. Bonome, D.A. Levine, J. Shih, M. Randonovich, C.A. Pise-Masison, F. Bogomolniy, L. Ozbun, J. Brady, J.C. Barrett, J. Boyd, M.J. Birrer, A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68, 5478–5486 (2008). doi:10.1158/0008-5472.CAN-07-6595 CrossRefPubMed T. Bonome, D.A. Levine, J. Shih, M. Randonovich, C.A. Pise-Masison, F. Bogomolniy, L. Ozbun, J. Brady, J.C. Barrett, J. Boyd, M.J. Birrer, A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68, 5478–5486 (2008). doi:10.​1158/​0008-5472.​CAN-07-6595 CrossRefPubMed
29.
Zurück zum Zitat E. Batlle, E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, A. Garcia De Herreros, The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84–89 (2000). doi:10.1038/35000034 CrossRefPubMed E. Batlle, E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, A. Garcia De Herreros, The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84–89 (2000). doi:10.​1038/​35000034 CrossRefPubMed
31.
Zurück zum Zitat B.P. Zhou, J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, M.C. Hung, Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931–940 (2004). doi:10.1038/ncb1173 CrossRefPubMed B.P. Zhou, J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, M.C. Hung, Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931–940 (2004). doi:10.​1038/​ncb1173 CrossRefPubMed
32.
Zurück zum Zitat D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789 (1995). doi:10.1038/378785a0 CrossRefPubMed D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789 (1995). doi:10.​1038/​378785a0 CrossRefPubMed
33.
Zurück zum Zitat A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, M.A. Nieto, The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76–83 (2000). doi:10.1038/35000025 CrossRefPubMed A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, M.A. Nieto, The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76–83 (2000). doi:10.​1038/​35000025 CrossRefPubMed
35.
Zurück zum Zitat H. Asechi, E. Hatano, T. Nitta, M. Tada, K. Iwaisako, N. Tamaki, H. Nagata, M. Narita, A. Yanagida, I. Ikai, S. Uemoto, Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 37, 89–96 (2010)PubMed H. Asechi, E. Hatano, T. Nitta, M. Tada, K. Iwaisako, N. Tamaki, H. Nagata, M. Narita, A. Yanagida, I. Ikai, S. Uemoto, Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 37, 89–96 (2010)PubMed
39.
Zurück zum Zitat R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, S. Fereday, M. Lawrence, S.L. Carter, C.H. Mermel, A.D. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, K. Levanon, C. Sougnez, A. Tsherniak, S. Gomez, R. Onofrio, S. Gabriel, L. Chin, N. Zhang, P.T. Spellman, Y. Zhang, R. Akbani, K.A. Hoadley, A. Kahn, M. Kobel, D. Huntsman, R.A. Soslow, A. Defazio, M.J. Birrer, J.W. Gray, J.N. Weinstein, D.D. Bowtell, R. Drapkin, J.P. Mesirov, G. Getz, D.A. Levine, M. Meyerson, Cancer genome atlas research, Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123, 517–525 (2013). doi:10.1172/JCI65833 PubMed R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, S. Fereday, M. Lawrence, S.L. Carter, C.H. Mermel, A.D. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, K. Levanon, C. Sougnez, A. Tsherniak, S. Gomez, R. Onofrio, S. Gabriel, L. Chin, N. Zhang, P.T. Spellman, Y. Zhang, R. Akbani, K.A. Hoadley, A. Kahn, M. Kobel, D. Huntsman, R.A. Soslow, A. Defazio, M.J. Birrer, J.W. Gray, J.N. Weinstein, D.D. Bowtell, R. Drapkin, J.P. Mesirov, G. Getz, D.A. Levine, M. Meyerson, Cancer genome atlas research, Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123, 517–525 (2013). doi:10.​1172/​JCI65833 PubMed
41.
Zurück zum Zitat D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, A.K. Godwin, J.R. Testa, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853–5857 (2004). doi:10.1038/sj.onc.1207721 CrossRefPubMed D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, A.K. Godwin, J.R. Testa, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853–5857 (2004). doi:10.​1038/​sj.​onc.​1207721 CrossRefPubMed
42.
Zurück zum Zitat A.J. Hanrahan, N. Schultz, M.L. Westfal, R.A. Sakr, D.D. Giri, S. Scarperi, M. Janakiraman, N. Olvera, E.V. Stevens, Q.B. She, C. Aghajanian, T.A. King, E. Stanchina, D.R. Spriggs, A. Heguy, B.S. Taylor, C. Sander, N. Rosen, D.A. Levine, D.B. Solit, Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2, 56–67 (2012). doi:10.1158/2159-8290.CD-11-0170 CrossRefPubMedPubMedCentral A.J. Hanrahan, N. Schultz, M.L. Westfal, R.A. Sakr, D.D. Giri, S. Scarperi, M. Janakiraman, N. Olvera, E.V. Stevens, Q.B. She, C. Aghajanian, T.A. King, E. Stanchina, D.R. Spriggs, A. Heguy, B.S. Taylor, C. Sander, N. Rosen, D.A. Levine, D.B. Solit, Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2, 56–67 (2012). doi:10.​1158/​2159-8290.​CD-11-0170 CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, C. Eng, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158, 2097–2106 (2001). doi:10.1016/S0002-9440(10)64681-0 CrossRefPubMedPubMedCentral K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, C. Eng, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158, 2097–2106 (2001). doi:10.​1016/​S0002-9440(10)64681-0 CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat M. Sun, G. Wang, J.E. Paciga, R.I. Feldman, Z.Q. Yuan, X.L. Ma, S.A. Shelley, R. Jove, P.N. Tsichlis, S.V. Nicosia, J.Q. Cheng, AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159, 431–437 (2001)CrossRefPubMedPubMedCentral M. Sun, G. Wang, J.E. Paciga, R.I. Feldman, Z.Q. Yuan, X.L. Ma, S.A. Shelley, R. Jove, P.N. Tsichlis, S.V. Nicosia, J.Q. Cheng, AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159, 431–437 (2001)CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, J.Q. Cheng, Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19, 2324–2330 (2000). doi:10.1038/sj.onc.1203598 CrossRefPubMed Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, J.Q. Cheng, Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19, 2324–2330 (2000). doi:10.​1038/​sj.​onc.​1203598 CrossRefPubMed
46.
Zurück zum Zitat L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, J.W. Gray, PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99–102 (1999). doi:10.1038/5042 CrossRefPubMed L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, J.W. Gray, PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99–102 (1999). doi:10.​1038/​5042 CrossRefPubMed
47.
Zurück zum Zitat K.E. Sheppard, C. Cullinane, K.M. Hannan, M. Wall, J. Chan, F. Barber, J. Foo, D. Cameron, A. Neilsen, P. Ng, J. Ellul, M. Kleinschmidt, K.M. Kinross, D.D. Bowtell, J.G. Christensen, R.J. Hicks, R.W. Johnstone, G.A. McArthur, R.D. Hannan, W.A. Phillips, R.B. Pearson, Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 49, 3936–3944 (2013). doi:10.1016/j.ejca.2013.08.007 CrossRefPubMed K.E. Sheppard, C. Cullinane, K.M. Hannan, M. Wall, J. Chan, F. Barber, J. Foo, D. Cameron, A. Neilsen, P. Ng, J. Ellul, M. Kleinschmidt, K.M. Kinross, D.D. Bowtell, J.G. Christensen, R.J. Hicks, R.W. Johnstone, G.A. McArthur, R.D. Hannan, W.A. Phillips, R.B. Pearson, Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 49, 3936–3944 (2013). doi:10.​1016/​j.​ejca.​2013.​08.​007 CrossRefPubMed
50.
Zurück zum Zitat G. Singer, R. Oldt 3rd, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, M. Shih Ie, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484–486 (2003)CrossRefPubMed G. Singer, R. Oldt 3rd, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, M. Shih Ie, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484–486 (2003)CrossRefPubMed
51.
Zurück zum Zitat A. Bagnato, L. Rosano, Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185, 85–94 (2007). doi:10.1159/000101307 CrossRefPubMed A. Bagnato, L. Rosano, Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185, 85–94 (2007). doi:10.​1159/​000101307 CrossRefPubMed
52.
Zurück zum Zitat Y. Yang, J. Zhang, Y. Zhu, Z. Zhang, H. Sun, Y. Feng, Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-snail signaling pathway. Int J Gynecol Cancer 24, 1564–1574 (2014). doi:10.1097/IGC.0000000000000279 CrossRefPubMed Y. Yang, J. Zhang, Y. Zhu, Z. Zhang, H. Sun, Y. Feng, Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-snail signaling pathway. Int J Gynecol Cancer 24, 1564–1574 (2014). doi:10.​1097/​IGC.​0000000000000279​ CrossRefPubMed
56.
Zurück zum Zitat Y. Zhang, C. Bao, Q. Mu, J. Chen, J. Wang, Y. Mi, A.J. Sayari, Y. Chen, M. Guo, Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells. Neoplasma 63, 362–370 (2016). doi:10.4149/304_150806N433 CrossRefPubMed Y. Zhang, C. Bao, Q. Mu, J. Chen, J. Wang, Y. Mi, A.J. Sayari, Y. Chen, M. Guo, Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells. Neoplasma 63, 362–370 (2016). doi:10.​4149/​304_​150806N433 CrossRefPubMed
57.
Zurück zum Zitat C.F. Hu, Y.Y. Huang, Y.J. Wang, F.G. Gao, Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells. Oncol Rep 36, 455–461 (2016). doi:10.3892/or.2016.4827 CrossRefPubMed C.F. Hu, Y.Y. Huang, Y.J. Wang, F.G. Gao, Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells. Oncol Rep 36, 455–461 (2016). doi:10.​3892/​or.​2016.​4827 CrossRefPubMed
Metadaten
Titel
HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation
verfasst von
Suresh Bugide
Vijay Kumar Gonugunta
Vasudevarao Penugurti
Vijaya Lakshmi Malisetty
Ratna K. Vadlamudi
Bramanandam Manavathi
Publikationsdatum
30.12.2016
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2017
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0308-2

Weitere Artikel der Ausgabe 2/2017

Cellular Oncology 2/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …